Research Article | Open Access
Feng Zhao, Yong Fang, Shuixiang Deng, Xiantao Li, Yun Zhou, Ye Gong, Hechen Zhu, Wei Wang, "Glycyrrhizin Protects Rats from Sepsis by Blocking HMGB1 Signaling", BioMed Research International, vol. 2017, Article ID 9719647, 10 pages, 2017. https://doi.org/10.1155/2017/9719647
Glycyrrhizin Protects Rats from Sepsis by Blocking HMGB1 Signaling
Background. HMGB1 acts as an important inflammatory mediator and is a potential therapeutic target for sepsis. Glycyrrhizin (GL), a natural triterpene glycoside derived from licorice, has been demonstrated to inhibit HMGB1 activity. The aim of this study is to explore how GL affects the HMGB1 signaling in sepsis. Methods. We used a CLP model of sepsis and in vitro LPS or HMGB1-treated NR8383 cells to examine the effects of GL on expression of HMGB1 and proinflammatory cytokines. Furthermore, we explored the effect of GL on interactions between HMGB1 and RAGE or TLR4 and the activations of NF-κB and MAPKs. Results. GL significantly decreased mortality and reduced serum levels of HMGB1 in vivo. GL also attenuated the release and expression of HMGB1 and proinflammatory cytokines. Direct stimulation by HMGB1 elevated the release of proinflammatory cytokines faster than LPS did and it was also inhibited by GL. Furthermore, GL blocked the interaction of HMGB1 with RAGE and TLR4 and suppressed the downstream MAPKs/NF-κB signaling pathway. Conclusion. GL may protect rats against sepsis by blocking the interaction of HMGB1 with cell surface receptors and HMGB1-mediated inflammatory responses.
Sepsis is one of the oldest problems in medicine, a systemic inflammatory response syndrome against documented or suspected infection . Because of the increasing number of aging patients and drug-resistant pathogens, the incidence of sepsis has increased to over 750,000 annual cases in the United States, costing nearly $17 billion every year . Sepsis and septic shock are the leading cause of death in intensive care units, with a mortality rate of more than 30% despite advances in critical care medicine . Current clinical therapies for sepsis are limited and include antibiotics, steroidal anti-inflammatory drugs, and early goal-directed therapies (EGDT), which were recommended as guidelines by the International Surviving Sepsis Campaign . Unfortunately, while three large randomized trials found that early administration of antibiotics could increase survival, EGDT did not significantly decrease mortality in septic shock patients compared with the usual care . These findings have prompted an ongoing search for the pathogenesis of sepsis and novel therapeutic methods.
In sepsis, various pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS), as well as damage-associated molecular patterns (DAMPs), can stimulate receptors on immune cells like macrophages and monocytes to trigger the release of early proinflammatory mediators (e.g., tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interferon-γ (IFN-γ)) and the late mediator high mobility group box-1 protein (HMGB1) . The excessive release of these mediators results in countless disturbances of the host immune system accompanied by tissue injury [6, 7]. HMGB1 was first identified as a non-histone DNA binding protein, which was then determined to act as a potential inflammatory cytokine involved in the systemic inflammatory response . HMGB1 is secreted from macrophages/monocytes in response to PAMPs, DAMPs, or proinflammatory cytokines and initiates cellular responses by binding several cell surface receptors, including the receptor for advanced glycation end products (RAGE) and toll-like receptors (TLRs) [9, 10]. The level of serum HMGB1 is significantly increased in patients with severe sepsis . Targeting HMGB1 may be an ideal therapy for sepsis and several studies have shown positive results [11–13].
Glycyrrhizin (GL), also known as glycyrrhizic acid, is a natural triterpene glycoside and the major active component of Gancao (licorice root), widely used as a sweetening and flavoring agent in food. As a traditional herbal medicine, GL has been used clinically as a hepatoprotective drug for more than 20 years in China and Japan . Mollica et al. showed that GL could decrease the concentration of HMGB1 by binding directly to it and therefore inhibit its chemoattractant and mitogenic activities . In a previous study, we used a porcine model of endotoxemia and found that GL could improve systemic hemodynamics, enhance pulmonary oxygen exchange, and protect against damage to multiple organs. These effects were attributed to its regulation of excessive immune responses by reducing the serum level and gene expression of HMGB1 and other proinflammatory cytokines . The results suggested that GL may act as a HMGB1 suppressor to exert its beneficial effects in sepsis. Most recently, GL was reported to prevent sepsis-induced mortality in rats , but the mechanism underlying GL regulation of HMGB1 functions in sepsis is still unclear.
In the present study, we established a rat model of cecal ligation and puncture (CLP) and evaluated the effects of GL on mortality and levels of serum proinflammatory cytokines including HMGB1 in vivo. We also observed the effects of GL treatment on secretion and expression of proinflammatory cytokines in vitro using rat alveolar macrophage NR8383 cells stimulated with LPS or HMGB1. Finally, the influence of GL on the interaction between HMGB1 and cell surface receptors and downstream signaling pathways was analyzed.
2. Materials and Methods
2.1. Experimental Sepsis Model
To evaluate the therapeutic potential of GL, a polymicrobial sepsis model induced by CLP was employed . Briefly, male Sprague-Dawley rats weighing 300–350 g were anesthetized by intraperitoneal injection of sodium pentobarbital (80 mg/kg) and a 1.5 cm midline abdominal incision was made. The cecum was ligated distal to the ileocecal valve without obstructing intestinal continuity. The ligated cecum was then punctured twice with an 18-gauge needle and gently compressed to extrude a small amount of fecal matter. The cecum was returned to the abdominal cavity and the incision was closed. The sham control rats underwent a laparotomy in which the cecum was exposed but not ligated or punctured. All animals received saline solution (3 ml/100 g) subcutaneously for resuscitation immediately after the surgery. This study was approved by the Animal Ethics Committee of Fudan University (Shanghai, China) and performed in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health .
2.2. Drug Administration
For survival rate analysis, rats with CLP were randomly divided into the CLP group () and CLP + GL group (; rats received intravenous administration of GL 12 h after CLP for three days) (GL was purchased from Sigma-Aldrich, St. Louis, MO, USA, CDS020796), which was subsequently divided into five groups according to the daily GL dosage (1 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, and 20 mg/kg, /group). For cytokine assays, rats were randomly divided into four groups: sham group (; rats underwent sham operations and received sterile distilled water), sham + GL group (; rats underwent sham operations and received 10 mg/kg GL for three days), CLP group (; rats were subjected to CLP and received sterile distilled water beginning 12 h after CLP for three days), and CLP + GL group (; rats received 10 mg/kg GL beginning 12 h after CLP for three days).
2.3. Measurement of Cytokine Levels
For in vivo assays, serum samples were collected at 0, 12, 30, and 60 h after CLP. For in vitro assays, culture medium supernatants were collected at 0, 6, 12, and 18 h after LPS or HMGB1 administration. The levels of HMGB1 (LSBio, Seattle, WA, USA), TNF-α, IL-1β, and IL-6 were determined using enzyme linked immunosorbent assay (ELISA) kits (all from R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.
2.4. Cell Culture
Rat alveolar macrophage NR8383 cells were obtained from the American Type Culture Collection (Rockville, MD, USA) and cultured in Ham’s F12K medium (Gibco, Waltham, MA, USA) supplemented with 15% FBS and 1% penicillin/streptomycin at 37°C. NR8383 cells were seeded in six-well plates at a density of 1 × 105 cells/well and stimulated by LPS (1 μg/ml, Sigma-Aldrich) or HMGB1 (1 μg/ml, R&D Systems) and incubated with or without GL (Minophagen Pharmaceutical Co., Tokyo, Japan).
2.5. Real-Time PCR
Total RNA was extracted from NR8383 cells using Trizol reagent (Invitrogen, Carlsbad, CA, USA) and reverse transcribed using the Superscript First Strand cDNA Synthesis Kit (Invitrogen) according to the manufacturer’s instructions. PCR amplification was carried out using a One Step SYBR® PrimeScript™ RT-PCR Kit (Takara, Otsu, Shiga, Japan) on a StepOnePlus real-time PCR system (Applied Biosystems, Foster City, CA, USA). The primers used for PCR are shown in Table 1. The cycling conditions were 5 min initial denaturation at 94°C followed by 40 cycles of denaturation at 94°C for 30 s, annealing at 60°C for 1 min and extension at 72°C for 1 min, and final extension at 72°C for 10 min. The relative levels of cytokine mRNAs were calculated by the method  and normalized to β-actin expression as endogenous control.
2.6. Coimmunoprecipitation Assay
After various treatments, NR8383 cells were washed with PBS and lysed using 1x RIPA buffer. Lysates were centrifuged at 12,000 for 10 min and then incubated overnight at 4°C with 5 μg/ml of either anti-RAGE monoclonal (Santa Cruz, Dallas, TX, USA) or anti-TLR4 monoclonal antibody (Abcam, Cambridge, UK) on protein A agarose beads (Sigma-Aldrich). Immune complexes were then washed with lysis buffer and boiled with SDS sample buffer for 5 min. Finally, the samples were assayed by western blotting.
2.7. Western Blotting
After being extracted with lysis buffer, equal amounts of cellular protein were resolved on 6%–12% SDS-PAGE gels and transferred to polyvinylidenedifluoride membranes. After blocking with 5% nonfat dry milk, the membranes were incubated overnight with different primary antibodies specific for HMGB1 (Abcam), RAGE (Santa Cruz), TLR4 (Abcam), p-IκBα, IκBα, p-JNK, JNK, p-ERK1/2, ERK1/2, p-P38, P38 (all from Cell Signaling Technology, Beverly, MA, USA), and β-actin (Abcam). After washing, the membranes were subsequently incubated with the appropriate peroxidase-conjugated secondary antibody (Abcam) for 1 h at room temperature. The blots were visualized using an enhanced chemiluminescence system (Amersham, Arlington Heights, IL, USA).
2.8. Statistical Analysis
Survival data were analyzed by the Kaplan-Meier test. Differences among groups were analyzed using one-way analysis of variance, followed by Tukey post hoc test. Data are presented as means ± standard error of the mean (SEM). The values < 0.05 were considered statistically significant.
3.1. GL Protects Rats against Lethal Sepsis
To evaluate the effect of GL against sepsis, a rat model of polymicrobial sepsis induced by CLP was established. Rats were treated with different doses of GL (1 to 20 mg/kg) for 3 days after CLP and animal survival rates were measured. As shown in Figure 1, sepsis induced by CLP produced 70% mortality in rats within 168 h after CLP, which was improved by increasing doses of GL, resulting in a significantly increased survival rate at 10 mg/kg.
3.2. GL Treatment Suppresses the Production of HMGB1 and Proinflammatory Cytokines in Septic Rats
HMGB1 is an important mediator of the inflammatory response which is always exaggerated in sepsis and contributes to the sepsis syndrome . As a potential antagonist of HMGB1 [15, 22], the effect of GL on HMGB1 release and proinflammatory cytokine production in septic rats was evaluated. As shown in Figure 2, plasma levels of TNF-α, IL-1, HMGB1, and IL-6 significantly increased after CLP, peaking at 12 h to 30 h. GL treatment did not affect the levels of HMGB1 and proinflammatory cytokines in sham control rats without CLP but did significantly attenuate circulating HMGB1 and proinflammatory cytokine levels in septic rats 30 h and 60 h after CLP.
3.3. GL Treatment Attenuated LPS-Induced HMGB1 and Proinflammatory Cytokine Release In Vitro
We then investigated potential anti-inflammatory effects of GL in vitro using LPS-stimulated rat alveolar macrophages, which are an important producer of HMGB1 and proinflammatory cytokines [23, 24]. The results showed that GL suppressed LPS-induced release of HMGB1, TNF-α, IL-1, and IL-6 in a dose-dependent manner after 12 h of LPS treatment (Figure 3). Real-time PCR assay showed that mRNA expression of HMGB1, TNF-α, IL-1, and IL-6 in NR8383 cells was also inhibited by GL compared with the LPS-stimulated group (Figure 4).
3.4. GL Treatment Attenuated HMGB1-Induced Proinflammatory Cytokine Release In Vitro
HMGB1 is considered a late mediator of lethal systemic inflammation in sepsis . The results showing that GL did not affect the release of TNF-α, IL-1, and IL-6 at 6 h (Figure 3) implied that HMGB1 was the target of GL. To verify that GL blocked the function of HMGB1 in macrophages, the production of proinflammatory cytokines in HMGB1-stimulated macrophages incubated with or without GL was evaluated. As shown in Figure 5, HMGB1 treatment induced the release of TNF-α, IL-1, and IL-6 in macrophages. GL at 50 μg/ml and 100 μg/ml significantly reduced the release of proinflammatory cytokines from 6 h to 18 h. Real-time PCR assays showed that HMGB1 could induce mRNA expression of TNF-α, IL-1, IL-6, and itself (Figure 6). GL suppressed HMGB1 and proinflammatory cytokine expression in HMGB1-stimulated macrophages in a dose-dependent manner (Figure 6).
3.5. GL Inhibits the MAPK/NF-κB Pathway by Blocking Binding of HMGB1 to RAGE and TLR4
As a late mediator of sepsis, HMGB1 could modulate the inflammatory cascade through interaction with receptors of various cell types and induce activation of intracellular signaling pathways. RAGE and TLR4 have been identified as the primary receptors for HMGB1 . Activation of these receptors results in the activation of NF-κB, which induces the production of proinflammatory cytokines [26, 27]. To explore the effect of GL on interactions between HMGB1 and RAGE or TLR4, coimmunoprecipitation assays were employed. As shown in Figure 7(a), either LPS or HMGB1 stimulation enhanced the interaction between HMGB1 and RAGE or TLR4, which was notably suppressed by GL incubation. We next analyzed the effect of GL on the activation of NF-κB by measuring the phosphorylation levels of IκBα. Higher levels of IκBα phosphorylation were detected after LPS or HMGB1 stimulation, indicating NF-κB activation (Figure 7(b)). In the presence of GL, IκBα phosphorylation was obviously decreased compared with untreated cells (Figure 7(b)). Furthermore, we determined the influence of GL on mitogen-activated protein kinase (MAPK) activation, including JNK, p38, and ERK, which have all been indicated to link activation of RAGE or TLR4 to phosphorylation and degradation of IκB [27, 28]. We confirmed that LPS and HMGB1 increased the phosphorylation of JNK, p38, and ERK in NR8383 cells. The increased phosphorylation of these MAPKs was appreciably attenuated by GL treatment, suggesting that GL inhibited LPS or HMGB1-induced MAPK activation.
In this study, we found that GL could protect rats against lethal sepsis induced by CLP and suppress the production of HMGB1 and proinflammatory cytokines in septic rats. GL treatment also attenuated the release and expression of HMGB1 and proinflammatory cytokines induced by LPS or HMGB1 in vitro. Furthermore, GL inhibited the MAPK/NF-κB pathway by blocking the binding of HMGB1 with RAGE and TLR4.
Our previous study evaluated the function of GL using an endotoxemia model, whereas a CLP model was used in the present study. This model has been used extensively to investigate the clinical settings of sepsis because it produces polymicrobial septicemia and the full spectrum of sepsis, ranging from acute to chronic pathophysiological processes . In our study, GL treatment at a dose of 10 mg/kg significantly decreased mortality caused by CLP. Interestingly, at the highest dose (20 mg/kg), GL showed reduced efficacy. Recently, Zhao et al.  found that 50 mg/kg of glycyrrhizic acid greatly improved the survival rate of rats with sepsis. These differences in the effective dose of GL may be caused by different treatment frequency. The appropriate dose and intervention time for the use of GL in sepsis will require further investigation.
Our previous study and other researches have shown the anti-inflammatory properties of GL in endotoxemia  and ischemia-reperfusion injury. Consistently, we found that GL significantly attenuated circulating HMGB1 and proinflammatory cytokine levels in septic rats. To investigate the underlying mechanism, we utilized LPS-stimulated rat alveolar macrophage NR8383 cells, which are a major source of proinflammatory cytokines. The results indicated that GL inhibited LPS-induced release of HMGB1, TNF-α, IL-1β, and IL-6, which can be attributed to the suppressive effect of GL on cytokine mRNA expression. Notably, the reductions in cytokine levels occurred after GL treatment for 12 h, implying that GL may function as an inhibitor of HMGB1 in LPS-stimulated NR8383 cells. This was further verified by the finding that GL could attenuate the release and expression of proinflammatory cytokines induced by direct HMGB1 stimulation at an early stage. Interestingly, our results showed that HMGB1 mRNA level could be regulated by HMGB1 treatment, implying that there may be a positive feedback and the mechanism is worth further exploration.
HMGB1 has been shown to induce proinflammatory cytokine expression through interaction with cell surface receptors and subsequent activation of intracellular signaling by MAPKs and NF-κB . In the present study, we found that, in addition to direct stimulation of HMGB1, LPS also enhanced the binding of HMGB1 to cell surface receptors TLR4 and RAGE, thereby activating the MAPK/NF-κB signaling pathway. This suggests that HMGB1 mediated the LPS-stimulated inflammatory cascade responses in rat macrophages. GL treatment reduced the interaction of HMGB1 with TLR4 and RAGE, probably by blocking the binding of HMGB1 fragments to TLR4 or RAGE. Schröfelbauer et al. found that the anti-inflammatory effects of GL were specific for membrane-dependent receptor-mediated stimuli , and our study provides an explanation for this. In agreement with our results, Okuma et al. also found that GL could suppress HMGB1-RAGE interaction in rats with traumatic brain injury . Recently, GL and GL derivative were shown to inhibit LPS-induced HMGB1 release from RAW264.7 cells [33, 34]; however, our results suggest that GL could also block the interaction of HMGB1 with its receptors.
In conclusion, GL may protect rats against lethal sepsis induced by CLP and suppress the production of proinflammatory cytokines in septic rats and LPS-stimulated rat macrophages. Furthermore, GL inhibited the expression of proinflammatory cytokines by blocking the interaction of HMGB1 with RAGE and TLR4, thereby inhibiting the downstream MAPK/NF-κB pathway.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
Feng Zhao and Yong Fang contributed equally to this paper.
This study was supported by a general project from Shanghai Municipal Commission of Health and Family Planning (Projects nos. 201540043 and 2016ZB0202-01) and Science and Technology Commission of Shanghai Municipality (Project no. 13ZR1405600).
- R. S. Hotchkiss and I. E. Karl, “The pathophysiology and treatment of sepsis,” The New England Journal of Medicine, vol. 348, no. 2, pp. 138–150, 2003.
- D. C. Angus, W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky, “Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care,” Critical Care Medicine, vol. 29, no. 7, pp. 1303–1310, 2001.
- E. K. Stevenson, A. R. Rubenstein, G. T. Radin, R. S. Wiener, and A. J. Walkey, “Two decades of mortality trends among patients with severe sepsis: a comparative meta-Analysis,” Critical Care Medicine, vol. 42, no. 3, pp. 625–631, 2014.
- R. G. Gupta, S. M. Hartigan, M. G. Kashiouris, C. N. Sessler, and G. M. L. Bearman, “Early goal-directed resuscitation of patients with septic shock: current evidence and future directions,” Critical Care, vol. 19, no. 1, article 286, 2015.
- W. J. Wiersinga, S. J. Leopold, D. R. Cranendonk, and T. van der Poll, “Host innate immune responses to sepsis,” Virulence, vol. 5, no. 1, pp. 36–44, 2014.
- T. Skirecki, U. Borkowska-Zielińska, M. Złotorowicz, and G. Hoser, “Sepsis immunopathology: perspectives of monitoring and modulation of the immune disturbances,” Archivum Immunologiae et Therapiae Experimentalis, vol. 60, no. 2, pp. 123–135, 2012.
- W. J. Kox, T. Volk, S. N. Kox, and H.-D. Volk, “Immunomodulatory therapies in sepsis,” Intensive Care Medicine, vol. 26, supplement 1, pp. S124–S128, 2000.
- H. Wang, O. Bloom, M. Zhang et al., “HMG-1 as a late mediator of endotoxin lethality in mice,” Science, vol. 285, no. 5425, pp. 248–251, 1999.
- M. A. D. Van Zoelen, H. Yang, S. Florquin et al., “Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo,” Shock, vol. 31, no. 3, pp. 280–284, 2009.
- W. S. Yang, N. J. Han, J. J. Kim, M. J. Lee, and S.-K. Park, “TNF-α activates high-mobility group box 1—toll-like receptor 4 signaling pathway in human aortic endothelial cells,” Cellular Physiology and Biochemistry, vol. 38, no. 6, pp. 2139–2151, 2016.
- K. Suda, Y. Kitagawa, S. Ozawa et al., “Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis,” World Journal of Surgery, vol. 30, no. 9, pp. 1755–1762, 2006.
- W. Li, M. Ashok, J. Li, H. Yang, A. E. Sama, and H. Wang, “A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1,” PLoS ONE, vol. 2, no. 11, Article ID e1153, 2007.
- C. Ye, J.-G. Choi, S. Abraham et al., “Human macrophage and dendritic cell-specific silencing of high-mobility group protein B1 ameliorates sepsis in a humanized mouse model,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 51, pp. 21052–21057, 2012.
- J.-y. Li, H.-y. Cao, P. Liu, G.-h. Cheng, and M.-y. Sun, “Glycyrrhizic acid in the treatment of liver diseases: literature review,” BioMed Research International, vol. 2014, Article ID 872139, 15 pages, 2014.
- L. Mollica, F. De Marchis, A. Spitaleri et al., “Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities,” Chemistry and Biology, vol. 14, no. 4, pp. 431–441, 2007.
- W. Wang, F. Zhao, Y. Fang et al., “Glycyrrhizin protects against porcine endotoxemia through modulation of systemic inflammatory response,” Critical Care, vol. 17, no. 2, article R44, 2013.
- H. Zhao, M. Zhao, Y. Wang, F. Li, and Z. Zhang, “Glycyrrhizic acid prevents sepsis-induced acute lung injury and mortality in rats,” Journal of Histochemistry and Cytochemistry, vol. 64, no. 2, pp. 125–137, 2016.
- G. Şener, H. Toklu, F. Ercan, and G. Erkanli, “Protective effect of β-glucan against oxidative organ injury in a rat model of sepsis,” International Immunopharmacology, vol. 5, no. 9, pp. 1387–1396, 2005.
- National Academy of Sciences, Guide for the Care and Use of Laboratory Animals, National Academy of Sciences, Washington, DC, USA, 2011.
- K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method,” Methods, vol. 25, no. 4, pp. 402–408, 2001.
- M. Bosmann and P. A. Ward, “The inflammatory response in sepsis,” Trends in Immunology, vol. 34, no. 3, pp. 129–136, 2013.
- Y. M. Kim, H. J. Kim, and K. C. Chang, “Glycyrrhizin reduces HMGB1 secretion in lipopolysaccharide-activated RAW 264.7 cells and endotoxemic mice by p38/Nrf2-dependent induction of HO-1,” International Immunopharmacology, vol. 26, no. 1, pp. 112–118, 2015.
- G. A. Duque and A. Descoteaux, “Macrophage cytokines: involvement in immunity and infectious diseases,” Frontiers in Immunology, vol. 5, article 491, 2014.
- M. T. Lotze and K. J. Tracey, “High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal,” Nature Reviews Immunology, vol. 5, no. 4, pp. 331–342, 2005.
- J. R. Van Beijnum, W. A. Buurman, and A. W. Griffioen, “Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1),” Angiogenesis, vol. 11, no. 1, pp. 91–99, 2008.
- C.-H. Hou, Y.-C. Fong, and C.-H. Tang, “HMGB-1 induces IL-6 production in human synovial fibroblasts through c-Src, Akt and NF-κB pathways,” Journal of Cellular Physiology, vol. 226, no. 8, pp. 2006–2015, 2011.
- T. Kawai and S. Akira, “Signaling to NF-κB by Toll-like receptors,” Trends in Molecular Medicine, vol. 13, no. 11, pp. 460–469, 2007.
- A. Taguchi, D. C. Blood, G. Del Toro et al., “Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases,” Nature, vol. 405, no. 6784, pp. 354–360, 2000.
- W. J. Hubbard, M. Choudhry, M. G. Schwacha et al., “Cecal ligation and puncture,” Shock, vol. 24, supplement 1, pp. 52–57, 2005.
- H. Zhao, M. Zhao, Y. Wang, F. Li, and Z. Zhang, “Glycyrrhizic acid attenuates sepsis-induced acute kidney injury by inhibiting NF-κB signaling pathway,” Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 8219287, 11 pages, 2016.
- B. Schröfelbauer, J. Raffetseder, M. Hauner, A. Wolkerstorfer, W. Ernst, and O. H. J. Szolar, “Glycyrrhizin, the main active compound in liquorice, attenuates pro-inflammatory responses by interfering with membrane-dependent receptor signalling,” Biochemical Journal, vol. 421, no. 3, pp. 473–482, 2009.
- Y. Okuma, K. Liu, H. Wake et al., “Glycyrrhizin inhibits traumatic brain injury by reducing HMGB1-RAGE interaction,” Neuropharmacology, vol. 85, pp. 18–26, 2014.
- C.-X. Wu, L.-X. He, H. Guo, X.-X. Tian, Q. Liu, and H. Sun, “Inhibition effect of glycyrrhizin in lipopolysaccharide-induced high-mobility group box 1 releasing and expression from RAW264.7 cells,” Shock, vol. 43, no. 4, pp. 412–421, 2015.
- W. Li, J. Li, A. E. Sama, and H. Wang, “Carbenoxolone blocks endotoxin-induced protein kinase R (PKR) activation and high mobility group box 1 (HMGB1) release,” Molecular Medicine, vol. 19, no. 1, pp. 203–211, 2013.
Copyright © 2017 Feng Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.